Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells

Journal of Immunotherapy

Volumn 28, Issue 1, 2005, Pages 28-39

  Hammond, Caitlin ^a,b   Shi, Yonghong ^a   Mena, Jenny ^a   Tomic, Jelena ^a,b   Cervi, David ^a,b   He, Liwei ^c   Millar, Amanda E ^c   DeBenedefte, Mark ^c   Schuh, Andre C ^b,c,d   Baryza, Jeremy L ^e   Wender, Paul A ^e   Radvanyi, Laszlo ^c   Spaner, David E ^a,b,f  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Aventis Pasteur   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e STANFORD UNIVERSITY   (United States)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

B lymphocytes; Cellular differentiation; Dendritic cells; Human; Th1 Th2 cells; Tumor immunity

Indexed keywords

ANTIOXIDANT; BRYOSTATIN; BRYOSTATIN 1; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; MERCAPTOETHANOL; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL DEATH; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FETAL CALF SERUM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 19944429146     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200501000-00004     Document Type: Article

References (49)

1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
2. Gitelson E, Hammond C, Mena J, et al. Chronic lymphocytic leukemia-reactive T cells during tumor progression and after oxidized autologous tumor cell vaccines. Clin Can Res. 2003;9:1656-1665.
3. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol. 2000;28:558-568.
4. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
5. Okamura J, Letarte M, Stein LD, et al. Modulation of chronic lymphocytic leukemia cells by phorbol ester: increase in Ia expression, IgM secretion and MLR stimulatory capacity. J Immunol. 1982; 128:2276-2280.
6. Barnes D, Sato G. Serum-free cell culture: a unifying approach. Cell. 1980;22:649-655.
7. Loo DT, Fuquay JI, Rawson CL, et al. Extended culture of mouse embryo cells without senescence: inhibition by serum. Science. 1987;236:200-202.
8. Clemens MJ, Trayner I, Menaya J. The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. J Cell Sci. 1992;103:881-887.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
10. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
11. Wender PA, Koehler MF, Sendzik M. A new synthetic approach to the C ring of known as well as novel bryostatin analogues. Org Lett. 2003;5:4549-4552.
12. Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002;260:157-172.
13. Lafreniere R, Borkenhagen K, Bryant LD, et al. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2. Cancer Res. 1989;49:2409-2414.
14. Ahmed SA, Gogal RMJ, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994;170:211-224.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
16. Totterman TH, Nilsson K, Sundstrom C. Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature. 1980;288:176-178.
17. Trimble LA, Xu Z, Lieberman J. Clonal expansion of antigen-specific CD8+ cytotoxic T lymphocytes is regulated by late exposure to serum to prevent apoptosis. J Immunol Methods. 1999;225:39-52.
18. Grandvaux N, Elsen S, Vignais PV. Oxidant-dependent phosphorylation of p40phox in B lymphocytes. Biochem Biophys Res Commun. 2001;287:1009-1016.
19. Pruett SB, Obiri N, Kiel JL. Involvement and relative importance of at least two distinct mechanisms in the effects of 2-mercaptoethanol on murine lymphocytes in culture. J Cell Physiol. 1989;141:40-45.
20. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA. 1988;85:9748-9752.
21. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:3854-3859.
22. Walter DH, Haendeler J, Galle J, et al. Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation. 1998;98:1153-1157.
23. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245-3287.
24. Vilpo J, Hulkkonen J, Hurme M, et al. Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells. Leukemia. 2002;16:1691-1698.
25. Wang QJ, Fang TW, Fenick D, et al. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J Biol Chem. 2000;275:12136-12146.
26. Krackhardt AM, Witzens M, Harig S, et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002;100:2123-2131.
27. Shakhov AN, Collart MA, Vassalli P, et al. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med. 1990;171:35-47.
28. de Waal MR, Abrams J, Bennett B, et al. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
29. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol. 2001;79:55-92.
30. Neumann M, Fries H, Scheicher C, et al. Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood. 2000;95:277-285.
31. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109:S81-96.
32. Jaken S. Protein kinase C and tumor promoters. Curr Opin Cell Biol. 1990;2:192-197.
33. Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21:924-936.
34. Drexler HG, Gignac SM, Jones RA, et al. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood. 1989;74:1747-1757.
35. Wender PA, Hinkle KW, Koehler MF, et al. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Med Res Rev. 1999;19:388-407.
36. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389-399.
37. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol. 2003;23:15-44.
38. Pai SY, Ho IC. c-Rel delivers a one-two punch in Th1 cell differentiation. J Clin Invest. 2002;110:741-742.
39. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
40. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
41. Lyakh LA, Koski GK, Telford W, et al. Bacterial lipopolysaccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14- monocytes through distinct pathways that activate NK-kappa B. J Immunol. 2000;165:3647-3655.
42. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
43. Corradi MP, Jelinek DF, Ramberg JE, et al. Development of a cell with dendritic morphology from a precursor of B lymphocyte lineage. J Immunol. 1987;138:2075-2081.
44. Davis TA, Saini AA, Blair PJ, et al. Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. J Immunol. 1998;160:3689-3697.
45. Celestin J, Rotschke O, Falk K, et al. IL-3 induces B7.2 (CD86) expression and costimulatory activity in human eosinophils. J Immunol. 2001;167:6097-6104.
46. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93:780-786.
47. Cignetti A, Bryant E, Allione B, et al. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood. 1999;94:2048-2055.
48. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113:1515-1525.
49. Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164:2200-2206.